Tuesday, AbbVie Inc (NYSE:ABBV) announced it received an FDA Complete Response Letter (CRL) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson’s disease. In its letter, the FDA cited observations…
Continue reading...